Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22751619 | 0.94 | PDK2 (0.32) | PDK2MEN1USP2KMT2AKEAP1 | |
| SCHEMBL20689996 | 0.91 | BCHE (0.31) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22751639 | 0.91 | PDK2 (0.34) | PDK2 | |
| SCHEMBL20689855 | 0.89 | LMNA (0.32) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL20689857 | 0.89 | LMNA (0.32) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22751657 | 0.89 | KDM4E (0.32) | MAPTMEN1KMT2A | |
| SCHEMBL22751711 | 0.89 | — | — | |
| SCHEMBL22751656 | 0.88 | BCHE (0.32) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22751655 | 0.86 | MAPT (0.33) | LMNAMAPTSMN1; SMN2MEN1USP2 | |
| SCHEMBL20689998 | 0.82 | KDM4E (0.31) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10862050-B2 | Heterocyclic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10862050-B2 | Heterocyclic compound and organic electroluminescence device including the same | CCNT1, CCNL2, CCNA1 | PDK2 342/4885LMNA 2930/4885MAPT 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.